|Comprehensive molecular portraits of human breast tumours|
Cancer Genome Atlas Network
Nature 490 (7418), 61-70, 2012
|Circulating tumor cells, disease progression, and survival in metastatic breast cancer|
M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ...
New England Journal of Medicine 351 (8), 781-791, 2004
|Supervised risk predictor of breast cancer based on intrinsic subtypes|
JS Parker, M Mullins, MCU Cheang, S Leung, D Voduc, T Vickery, ...
Journal of clinical oncology 27 (8), 1160-1167, 2009
|Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer|
MCU Cheang, SK Chia, D Voduc, D Gao, S Leung, J Snider, M Watson, ...
JNCI: Journal of the National Cancer Institute 101 (10), 736-750, 2009
|The molecular portraits of breast tumors are conserved across microarray platforms|
Z Hu, C Fan, DS Oh, JS Marron, X He, BF Qaqish, C Livasy, LA Carey, ...
BMC genomics 7 (1), 96, 2006
|Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1–and/or ErbB-2–positive, estrogen receptor–positive primary breast cancer: evidence from a …|
MJ Ellis, A Coop, B Singh, L Mauriac, A Llombert-Cussac, F Jänicke, ...
Journal of Clinical Oncology 19 (18), 3808-3816, 2001
|Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group|
M Dowsett, TO Nielsen, R A’Hern, J Bartlett, RC Coombes, J Cuzick, ...
Journal of the National Cancer Institute 103 (22), 1656-1664, 2011
|Genome remodelling in a basal-like breast cancer metastasis and xenograft|
LI Ding, MJ Ellis, S Li, DE Larson, K Chen, JW Wallis, CC Harris, ...
Nature 464 (7291), 999, 2010
|Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer|
M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ...
Journal of Clinical Oncology 23 (7), 1420-1430, 2005
|Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival|
DF Hayes, M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, MC Miller, ...
Clinical Cancer Research 12 (14), 4218-4224, 2006
|Whole-genome analysis informs breast cancer response to aromatase inhibition|
MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ...
Nature 486 (7403), 353, 2012
|Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study|
W Eiermann, S Paepke, J Appfelstaedt, A Llombart-Cussac, J Eremin, ...
Annals of Oncology 12 (11), 1527-1532, 2001
|Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer|
GT Budd, M Cristofanilli, MJ Ellis, A Stopeck, E Borden, MC Miller, ...
Clinical Cancer Research 12 (21), 6403-6409, 2006
|Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in …|
HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'neil, ...
Journal of Clinical Oncology 23 (23), 5305-5313, 2005
|Prospective validation of a 21-gene expression assay in breast cancer|
JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ...
New England Journal of Medicine 373 (21), 2005-2014, 2015
|Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on …|
CK Osborne, J Pippen, SE Jones, LM Parker, M Ellis, S Come, SZ Gertler, ...
Journal of Clinical Oncology 20 (16), 3386-3395, 2002
|Proteogenomic characterization of human colon and rectal cancer|
B Zhang, J Wang, X Wang, J Zhu, Q Liu, Z Shi, MC Chambers, ...
Nature 513 (7518), 382, 2014
|HER2 and response to paclitaxel in node-positive breast cancer|
DF Hayes, AD Thor, LG Dressler, D Weaver, S Edgerton, D Cowan, ...
New England Journal of Medicine 357 (15), 1496-1506, 2007
|A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor–positive breast cancer|
TO Nielsen, JS Parker, S Leung, D Voduc, M Ebbert, T Vickery, SR Davies, ...
Clinical Cancer Research 16 (21), 5222-5232, 2010
|Proteogenomics connects somatic mutations to signalling in breast cancer|
P Mertins, DR Mani, KV Ruggles, MA Gillette, KR Clauser, P Wang, ...
Nature 534 (7605), 55, 2016